← Back to patent-cliff list
Fulimetibant
Tier C — Watch / tradeFulimetibant
Bayer
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BDKRB1
Indications (approved)：神经痛, Diabetes, 糖尿病周围神经病变, Diabetic neuropathy, Renal impairment, Endometriosis
Regional status
US
-
EU
Phase II
2022-02-16
China
-
Japan
Phase I
2022-10-11
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fulimetibant?
Approved indications include: 神经痛, Diabetes, 糖尿病周围神经病变, Diabetic neuropathy, Renal impairment, Endometriosis.
When does the Fulimetibant patent expire?
No public expiry year is available for Fulimetibant yet; this page updates once verified.
How do I get a quote for Fulimetibant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05